FDA decisions expected in cardiology, nephrology, and oncology; Hopkins to host 2 eye conferences

Lynne Peterson is Senior Writer for Trends-in-Medicine.

Here is the medical news to watch for Jan. 18-24, 2021.

Cardiology: The FDA is expected to make a decision by Jan. 20 on an oral soluble guanylate cyclase stimulator (Merck MSD and Bayer’s vericiguat) to treat heart failure with reduced ejection fraction (HFrEF).

Nephrology: The FDA is expected to make a decision by Jan. 22 on a calcineurin inhibitor (Aurinia Pharmaceuticals’ voclosporin) to treat lupus nephritis.

Oncology: The FDA is expected to make a decision by Jan. 23 on expanded approval of crizotinib (Pfizer’s Xalkori), an ALK inhibitor, to include treatment of pediatric patients with relapsed or refractory anaplastic large cell lymphoma that is ALK positive.

Ophthalmology: Johns Hopkins University will host two virtual meetings:

  • Atlantic Coast Retina Conference on Jan. 22. The meeting will include a series of case presentations that apply recent trial data to clinical practice.
  • Macula 2021 on Jan. 23 will focus on new information about the use of biologic agents to treat neovascular and non-neovascular forms of age-related macular degeneration, vitreomacular interface abnormalities, diabetic retinopathy, intraocular tumors, and posterior uveitis.

Regulatory: Interestingly, there are zero FDA regulatory meetings this week.

Lynne Peterson, Contributing Writer, Senior Writer for Trends-in-Medicine

Cat ID: 3

Topic ID: 74,3,730,3,467,127,192,150,725,925,240